Pharmaceutical News

RSS

Prevenar 13 launched in first childhood immunization program for PD in Nicaragua

Pfizer Inc. announced that Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) was introduced into the first childhood immunization program for pneumococcal disease (PD) in the developing world under the auspices of the Advance Market Commitment (AMC) when Nicaragua launched its program today. The AMC is an innovative program which involves private-public partnerships to help make newer vaccines available on a sustainable, affordable and accelerated basis to the least developed countries.

13 Dec 2010

ORNL's software scans molecular databases, may help scientists to develop new drug treatments

A quicker and cheaper technique to scan molecular databases developed at the Department of Energy's Oak Ridge National Laboratory could put scientists on the fast track to developing new drug treatments.

13 Dec 2010

Man Up Now capsules can dangerously lower blood pressure

Product marketed for sexual enhancement contains potentially dangerous ingredient The U.S. Food and Drug Administration is warning consumers not to use Man Up Now capsules, marketed as a dietary supplement for sexual enhancement, because they contain a variation of an active drug ingredient found in Viagra that can dangerously lower blood pressure.

13 Dec 2010

Exemestane may provide post-surgery option for postmenopausal women with hormone-receptor positive breast cancer

Exemestane, an aromatase inhibitor that blocks production of estrogen, may provide another post-surgery option for postmenopausal women with hormone-receptor positive, early-stage breast cancer.

13 Dec 2010

Combination therapy improves tumor response in HER2-positive breast cancer patients

A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

13 Dec 2010

Denosumab delays skeletal-related side effects in patients with breast cancer and bone metastases

For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared to those on zoledronic acid, according to results presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

13 Dec 2010

Depression drug appears effective in reducing pain associated with breast cancer treatment

A drug commonly used to treat depression and anxiety disorder was effective at reducing joint and muscle pain associated with a breast cancer treatment, according to a study from the University of Michigan Comprehensive Cancer Center.

12 Dec 2010

New challenges to FDA's 'no risk' classification of mercury fillings

FDA Device Division, still concerned about mercury toxicity in American dentistry, is convening yet another professional panel review regarding safety issues. A nationwide convergence of scientists, dental and medical professionals, lead by the International Academy of Oral Medicine and Toxicology (IAOMT) are provoking new challenges to the Food and Drug Administration's (FDA) July'09 "no risk" classification of mercury fillings .

10 Dec 2010

Pfizer withdraws Thelin for treatment of PAH, discontinues global clinical studies

Pfizer Inc. announced today that, in the interest of patient safety, it is voluntarily withdrawing Thelin® (sitaxentan) for the treatment of pulmonary arterial hypertension (PAH) in regions where it is approved (the European Union, Canada and Australia). In addition, Pfizer is discontinuing clinical studies of Thelin worldwide.

10 Dec 2010

FDA approves Mylan's generic Adalat CC Tablets ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nifedipine Extended-release Tablets USP, 30 mg, 60 mg and 90 mg, the generic version of Bayer's Adalat® CC Tablets, a treatment for hypertension.

10 Dec 2010

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although platinum-based treatment will continue to be the standard of care for first- and second-line treatment of platinum-sensitive ovarian cancer, pegylated liposomal doxorubicin (PLD)/carboplatin will replace paclitaxel/carboplatin as the standard second-line treatment for patients who remain platinum sensitive.

10 Dec 2010

Pisgah's technology imparts abuse deterrence to commonly abused prescription drugs

Pisgah Labs announced today the findings from a proof of concept study confirming Pisgah's technology imparts abuse deterrence to commonly abused prescription drugs, particularly narcotics. The controlled study, conducted in dogs, was performed with the un-formulated active ingredient, hydrocodone, as modified according to a host of patent applications filed by Pisgah Labs with the United States Patent and Trademark Office (http://www.uspto.gov).

10 Dec 2010

Serodus licenses selective serotonin-4 antagonist for potential heart failure treatment from Roche

Serodus AS today announced that it has entered into a license agreement with Roche for a selective serotonin-4 (5-HT4) antagonist for the potential treatment of heart failure (RO1160367).

10 Dec 2010

Using buprenorphine to treat opioid-dependent pregnant women may result in healthier babies

Using buprenorphine instead of methadone — the current standard of care — to treat opioid-dependent pregnant women may result in healthier babies, suggests new findings from an international team led by Johns Hopkins researchers and published in the Dec. 9 issue of the New England Journal of Medicine.

10 Dec 2010

McNeil recalls ROLAIDS Ultra Strength SoftChews and SoftChews plus Gas Relief in Canada

McNeil Consumer Healthcare, Division of Johnson & Johnson Inc. is voluntarily recalling all lots of ROLAIDS® Ultra Strength SoftChews® and ROLAIDS® Ultra Strength SoftChews® plus Gas Relief distributed in Canada.

10 Dec 2010

PharmaDirections congratulates Orexigen on FDA Advisory approval for Contrave

PharmaDirections congratulates Orexigen Therapeutics on achieving FDA Advisory Board approval for their anti-obesity drug Contrave™. PharmaDirections is proud to have been Orexigen's pharmaceutical development partner and to have developed and produced the first Contrave™ product to undergo full clinical development.

10 Dec 2010

News outlets report on polio outbreaks in Central, East Africa

"Bad immunisation strategy has been blamed for an outbreak of polio, which has killed nearly 200 and is believed to have caused paralysis in more than 2,000 others across Angola, Congo and the Democratic Republic of the Congo," the Mail & Guardian writes in a story examining the emergence of the disease in the three countries and efforts to control it.

10 Dec 2010

FDA grants approval to manufacture Collagenase SANTYL Ointment at DPT Laboratories' facility

Healthpoint today announced that the U.S. Food and Drug Administration has granted approval to manufacture commercial supplies of Collagenase SANTYL Ointment, a biologic enzymatic debriding agent, at DPT Laboratories' Center of Excellence for Sterile & Specialty Products facility in Lakewood, New Jersey.

10 Dec 2010

New three-drug combination may be effective for newly diagnosed blood cancer patients: Study

A new three-drug combination used to treat the blood cancer multiple myeloma may be effective as a front-line therapy for newly diagnosed patients, according to a study led by the University of Michigan Comprehensive Cancer Center.

9 Dec 2010

Warfarin may not be beneficial to some patients with atrial fibrillation: Researchers

Researchers at the University of Cincinnati and Massachusetts General Hospital have found that warfarin, a known anticoagulation (blood-thinning) drug, may not be as beneficial to some patients with atrial fibrillation as previously thought.

9 Dec 2010

Pharmaceutical News

Prevenar 13 launched in first childhood immunization program for PD in Nicaragua

ORNL's software scans molecular databases, may help scientists to develop new drug treatments

Man Up Now capsules can dangerously lower blood pressure

Exemestane may provide post-surgery option for postmenopausal women with hormone-receptor positive breast cancer

Combination therapy improves tumor response in HER2-positive breast cancer patients

Denosumab delays skeletal-related side effects in patients with breast cancer and bone metastases

Depression drug appears effective in reducing pain associated with breast cancer treatment

New challenges to FDA's 'no risk' classification of mercury fillings

Pfizer withdraws Thelin for treatment of PAH, discontinues global clinical studies

FDA approves Mylan's generic Adalat CC Tablets ANDA

PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer

Pisgah's technology imparts abuse deterrence to commonly abused prescription drugs

Serodus licenses selective serotonin-4 antagonist for potential heart failure treatment from Roche

Using buprenorphine to treat opioid-dependent pregnant women may result in healthier babies

McNeil recalls ROLAIDS Ultra Strength SoftChews and SoftChews plus Gas Relief in Canada

PharmaDirections congratulates Orexigen on FDA Advisory approval for Contrave

News outlets report on polio outbreaks in Central, East Africa

FDA grants approval to manufacture Collagenase SANTYL Ointment at DPT Laboratories' facility

New three-drug combination may be effective for newly diagnosed blood cancer patients: Study

Warfarin may not be beneficial to some patients with atrial fibrillation: Researchers

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News